Allergic Conjunctivitis - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 66 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Allergic Conjunctivitis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Allergic Conjunctivitis - Pipeline Review, H2 2014', provides an overview of the Allergic Conjunctivitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Conjunctivitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Allergic Conjunctivitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Allergic Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Allergic Conjunctivitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Allergic Conjunctivitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Allergic Conjunctivitis Overview 7
Therapeutics Development 8
Pipeline Products for Allergic Conjunctivitis - Overview 8
Pipeline Products for Allergic Conjunctivitis - Comparative Analysis 9
Allergic Conjunctivitis - Therapeutics under Development by Companies 10
Allergic Conjunctivitis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Allergic Conjunctivitis - Products under Development by Companies 15
Allergic Conjunctivitis - Companies Involved in Therapeutics Development 16
Alcon, Inc. 16
Allergan, Inc. 17
Oxagen Limited 18
Xencor, Inc. 19
Celsus Therapeutics Plc 20
Ohr Pharmaceutical Inc. 21
Laila Pharmaceuticals Pvt. Ltd. 22
Eleven Biotherapeutics 23
Griffin Discoveries BV 24
Allergic Conjunctivitis - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
olopatadine hydrochloride - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
cetirizine hydrochloride - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AGN-229666 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
dexamethasone acetate SR - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
OC-459 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
AL-53817 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
EBI-005 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
LP-00209 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
XmAb-7195 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
OPX-1 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
SUN-0597 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecules to Antagonize Histamine H1/H4 Receptor for Ophthalmology and Asthma - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
GD-134 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
KBP-7306 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Drugs for Allergic Conjunctivitis - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Allergic Conjunctivitis - Recent Pipeline Updates 51
Allergic Conjunctivitis - Dormant Projects 58
Allergic Conjunctivitis - Discontinued Products 59
Allergic Conjunctivitis - Product Development Milestones 60
Featured News & Press Releases 60
Mar 04, 2014: Eleven Biotherapeutics Reports Clinical and Regulatory Updates for EBI-005 60
Nov 25, 2013: Santen Launches Alesion 0.05% Ophthalmic Solution for Allergic Conjunctivitis Treatment in Japan 61
Sep 20, 2013: Santen Announces Approval of Alesion 0.05% Ophthalmic Solution for Allergic conjunctivitis Treatment in Japan 61
Apr 17, 2013: Celsus Therapeutics Receives US Patent Covering Product Candidate OPX-1 For Treatment Of Conjunctivitis 61
Nov 27, 2012: Santen Pharma Files For Manufacturing And Marketing Approval Of Anti-Allergic Ophthalmic Solution, DE-114 62
Jul 02, 2012: Faes Farma Receives Approval For Bilastine In Mexico 62
May 24, 2011: Alcon Wins Patanol US Patent Infringement Lawsuit Against Apotex 62
Mar 22, 2011: ISTA Pharmaceuticals Highlights BEPREVE Clinical Data At 2011 American Academy of Allergy, Asthma and Immunology Annual Meeting 63
Nov 26, 2010: Restasis gets Health Canada approval 64
Sep 16, 2010: Akorn Receives FDA Approval For Erythromycin Ophthalmic Ointment USP 1g 64
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 66
Disclaimer 66

List of Tables
Number of Products under Development for Allergic Conjunctivitis, H2 2014 8
Number of Products under Development for Allergic Conjunctivitis - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Allergic Conjunctivitis - Pipeline by Alcon, Inc., H2 2014 16
Allergic Conjunctivitis - Pipeline by Allergan, Inc., H2 2014 17
Allergic Conjunctivitis - Pipeline by Oxagen Limited, H2 2014 18
Allergic Conjunctivitis - Pipeline by Xencor, Inc., H2 2014 19
Allergic Conjunctivitis - Pipeline by Celsus Therapeutics Plc, H2 2014 20
Allergic Conjunctivitis - Pipeline by Ohr Pharmaceutical Inc., H2 2014 21
Allergic Conjunctivitis - Pipeline by Laila Pharmaceuticals Pvt. Ltd., H2 2014 22
Allergic Conjunctivitis - Pipeline by Eleven Biotherapeutics, H2 2014 23
Allergic Conjunctivitis - Pipeline by Griffin Discoveries BV, H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 29
Number of Products by Stage and Route of Administration, H2 2014 31
Number of Products by Stage and Molecule Type, H2 2014 33
Allergic Conjunctivitis Therapeutics - Recent Pipeline Updates, H2 2014 51
Allergic Conjunctivitis - Dormant Projects, H2 2014 58
Allergic Conjunctivitis - Discontinued Products, H2 2014 59